Szu-Yu Huang

Szu-Yu Huang

Auto-generated profile, based on publicly available information

Szu-Yu Huang

Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2023 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
SHSzu‐Yu Huang
Szu‐Yu Huang
YCYing‐Yi Chen
Ying‐Yi Chen
CTChing‐Chang Tsai
Ching‐Chang Tsai
HLHao Lin
Hao Lin
YOYu-Che Ou
Yu-Che Ou

1 March 2025 in Cancer Biomarkers
Verified
Journal Article
Open access
HLHao Lin
Hao Lin
HFHung-Chun Fu
Hung-Chun Fu
SHSzu-Yu Huang
Szu-Yu Huang
CWChen-Hsuan Wu
Chen-Hsuan Wu
SHSzu Wei Huang
Szu Wei Huang
YOYu-Che Ou
Yu-Che Ou
Background: We previously utilized pretreatment tumor markers Carcinoembryonic Antigen (CEA) and Cancer Antigen 125 (CA125) for predicting lymph node metastasis (LNM) in endometrioid endometrial cancer (EC). Objective: The aim of this study was to externally validate a nomogram developed in our previous single-center retrospective study. Methods: A multi-center validation study was conducted to recruit endometrioid EC patients from four branches of Chang Gung Memorial Hospital between 2009 and 2021, with patients participating in the original research being excluded. The previously established nomogram was applied with optimal cut-off values for CEA 1.4 ng/ml and CA125 40 U/mL identified through receiver operating characteristic (ROC) curves. The concordance index (C-index) was calculated to assess discrimination, and comparative negative predictive value (NPV) and negative likelihood ratio (NLR) were determined. Decision curve analysis (DCA) was plotted to evaluate our predictive model's clinical utility and net benefit. Results: Overall, 1271 patients were included in this external validation study. The results demonstrated a C-index of 0.727, indicating moderate discrimination ability of the nomogram in predicting LNM in this independent cohort. Comparative analysis of NPV 97.2% and NLR 0.36 revealed performance metrics consistent with the original study, reinforcing the nomogram's potential clinical utility in ruling out the possibility of LNM if both pretreatment CEA and CA125 were less than 1.4 ng/ml and 40 U/mL, respectively. The DCA indicated that the nomogram provided clinical utility. Conclusion: The reproducible performance metrics in the independent large sample cohort underscore the robustness and generalizability of utilizing CEA and CA125 as predictors of LNM in endometrioid EC, suggesting its potential as a simple tool for clinicians in preoperative decision-making regarding lymphadenectomy.

1 January 2026 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
SHSzu-Yu Huang
Szu-Yu Huang
HLHao Lin
Hao Lin
YOYu-Che Ou
Yu-Che Ou
HFHung-Chun Fu
Hung-Chun Fu
CTChing-Chou Tsai
Ching-Chou Tsai
CWChen-Hsuan Wu
Chen-Hsuan Wu
Huang SY, et al. J Gynecol Oncol. 2026 ;38:e10. https://doi.org/10.3802/jgo.2027.38.e10